Bioclinical markers in breast cancer: Updates and perspectives

Maria Di Vita, Massimiliano Berretta, Antonio Zanghi, Bruno Cacopardo, Andrea Cavallaro, Davide Lombardi, Emanuele Lo Menzo, Alessandro Cappellani

Research output: Contribution to journalArticlepeer-review


Molecular studies have definitely changed our knowledge of the biology of cancers, and breast cancer's tremendous social impact has stimulated a large mass of research. Classic markers have opened a road, but their usefulness appears limited to prognosis or follow up, while several new markers, both genetic and molecular, are assuming different, yet still controversial, importance: they may play a major role in the surveillance of subjects at risk, in detecting primary or recurrent cancers, and in predicting the need of adjuvant therapy, or the response to therapy. Nevertheless, the mandatory routine markers out of trials are not really modified when compared to the 2007 guidelines, essentially due to a lack of appropriate levels of evidence. For this reason we can only recommend to include as many women as possible in specific trials, in order to reach the evidence level that we need to substantially improve our understanding of cancer and eventually the outcome for women with breast cancer.

Original languageEnglish
Pages (from-to)343-358
Number of pages16
JournalFrontiers in Bioscience - Scholar
Volume2 S
Issue number1
Publication statusPublished - Jan 1 2010


  • Breast cancer
  • Follow Up
  • Markers
  • Prognosis
  • Review
  • Screening
  • Therapies

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Medicine(all)


Dive into the research topics of 'Bioclinical markers in breast cancer: Updates and perspectives'. Together they form a unique fingerprint.

Cite this